What's Happening?
The Supreme Court has upheld the conviction of the Korean telemedicine platform Doctornow for illegally advertising prescription drugs through its app. The ruling dismissed appeals by Doctornow and its former
CEO, Jang Ji-ho, on charges of violating the Pharmaceutical Affairs Act. The case centered on a feature called 'Get the Prescription You Want,' offered by Doctornow from May 10 to June 22, 2022. This feature allowed users to select drugs, add them to a shopping cart, and request prescriptions during remote consultations. Additionally, a 'Best Drugs' section listed prescription medicines by category, including treatments for skin conditions, hair loss, and weight loss, along with drug names, prices, effects, and patient reviews. The court found that this feature constituted advertising because it encouraged the use of specific prescription drugs, even without a direct commercial motive to increase sales.
Why It's Important?
This Supreme Court decision sets a significant precedent for telemedicine platforms, emphasizing the strict regulations surrounding prescription drug advertising. The ruling clarifies that even features designed to provide information can be deemed illegal advertising if they encourage the use of specific prescription drugs. This has broad implications for how telemedicine companies design their platforms and present drug-related content to users. It underscores the need for clear distinctions between informational services and promotional activities to avoid legal repercussions. For consumers, this ruling aims to protect against potentially misleading or undue influence in their prescription drug choices, promoting patient safety and informed medical decisions. The decision could prompt other telemedicine providers to review and revise their current practices to ensure compliance with advertising laws.
What's Next?
While the Supreme Court has upheld the conviction, Doctornow has separately filed a constitutional complaint questioning the clarity of the legal provision prohibiting prescription drug advertising. This constitutional challenge seeks to establish clearer standards for distinguishing between providing drug information and advertising, particularly as patients increasingly access such information through digital platforms and AI tools. The outcome of this separate constitutional review will be crucial for the future regulatory landscape of telemedicine. Depending on the Constitutional Court's decision, there could be further clarification or adjustments to the Pharmaceutical Affairs Act, impacting how telemedicine platforms operate and communicate about prescription drugs. The industry will be closely watching these developments to understand the evolving legal boundaries.
Beyond the Headlines
The Doctornow case highlights the ongoing tension between technological innovation in healthcare and existing regulatory frameworks. As telemedicine platforms offer increasingly sophisticated ways for patients to access medical services and information, regulators face the challenge of adapting laws designed for traditional healthcare models. This case underscores the need for a nuanced approach that fosters innovation while safeguarding public health. The debate over what constitutes 'advertising' in a digital context, especially for prescription drugs, is complex. It involves balancing patient autonomy and access to information with the potential for commercial influence. The resolution of Doctornow's constitutional complaint could significantly shape the ethical guidelines and legal interpretations for digital health services globally, influencing how information is presented and consumed in the digital age.





